GLP-1 and Blindness: What the New FDA Warning Means
Understand the new FDA GLP-1 eye warning, NAION risk, diabetic retinopathy, and when vision changes need urgent care.
Epitalon (Epithalon): Longevity Research and Its Limits
Understand Epitalon and epithalon research, how they differ from epithalamin, and why telomere or sleep biomarkers do not prove longer human life.
BPC-157 vs. TB-500: Evidence and Key Differences
Compare BPC-157 and TB-500 by exact molecule, human research, formulation and unanswered safety questions without assuming either improves recovery.
MOTS-c for Weight Loss: What Human Evidence Shows
Does MOTS-c cause weight loss in people? Separate administered-peptide evidence from exercise measurements, animal findings and analogue studies.
KPV for Gut Health: What Is Known About IBS and Inflammation?
Evaluate KPV gut-health claims by distinguishing IBS, IBD, cell signaling and mouse colitis from demonstrated outcomes in human patients.
Oral BPC-157 vs. Injections: Absorption and Evidence
Compare oral and injectable BPC-157 by absorption, formulation-specific evidence, clinical outcomes and quality questions rather than assumed equivalence.
Semax for Focus and Brain Fog: Evidence and Unanswered Questions
Examine Semax focus and brain-fog claims, what small human studies measured, and why imaging or stroke findings do not prove everyday cognitive benefits.
Epitalon and Telomeres: Does the Research Show Longer Life?
Trace Epitalon telomere findings from cultured cells to the unanswered human-longevity question, without equating a biomarker with longer life.
MOTS-c vs. GLP-1 Medicines: Why They Are Different
Compare MOTS-c with FDA-approved Wegovy injection by mechanism, clinical evidence, indications and safety without implying equivalence or substitution.
BPC-157 and TB-500 Blends: Does the HHS Policy Cover Them?
Why the HHS single-ingredient condition does not cover BPC-157/TB-500 blends, and why separate-vial use is not an automatic workaround.
